Wanbury Ltd Stock Price Today (NSE: WANBURY)
Fundamental Score
Wanbury Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Wanbury Ltd share price today is ₹221.95, up +0.00% on NSE/BSE as of 30 March 2026. Wanbury Ltd (WANBURY) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹895.00 (Cr). The 52-week high for WANBURY share price is ₹329.70 and the 52-week low is ₹161.50. At a P/E ratio of 20.82x, WANBURY is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 76.52% and a debt-to-equity ratio of 3.02.
Wanbury Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Wanbury Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Wanbury Share Price Analysis: A Conservative Value Investor's Perspective
The pharmaceutical sector, while offering defensive characteristics due to consistent healthcare demand, necessitates a discerning eye for value. The sustainability of drug pricing and regulatory hurdles contribute to inherent risks that warrant a cautious, fundamental-driven investment approach. This analysis examines the Wanbury share price from the perspective of a conservative value investor, prioritizing capital safety and long-term viability. The current price is ₹245.27.
Wanbury Ltd presents a mixed picture. A price-to-earnings (PE) ratio of 20.82 suggests that the market anticipates continued growth, a factor that requires careful scrutiny. The crucial factor here is the quality of the company's management. Wanbury Ltd and its peers like
Mankind Pharma Ltd need to be compared across numerous management efficiency ratios. A detailed comparison reveals a clearer picture of Wanbury's leadership capabilities relative to competitors like Mankind Pharma Ltd, allowing for a more informed judgment on the sustainability of future earnings. However, conservative investors would likely consider this valuation potentially rich in the current market environment.A standout metric for Wanbury is its Return on Capital Employed (ROCE) of 36.68%. This exceptionally high ROCE, if sustainable, speaks to efficient capital allocation and potentially a durable competitive advantage, often referred to as a "moat." A high ROCE suggests that the company is generating significant returns on its investments, implying pricing power, efficient operations, or a combination of both. However, the long-term sustainability of this ROCE needs thorough investigation. Can the company maintain this level of profitability in the face of generic competition, pricing pressures, and changing regulatory landscapes? Historical trends and industry dynamics are critical to assess this crucial aspect.
This analysis forms part of a comprehensive, 80-parameter fundamental audit, personally verified by Sweta Mishra. The aim is to provide an objective assessment of Wanbury's financial health and future prospects from a value investing standpoint. The focus is on understanding the company's intrinsic value, prioritizing capital preservation, and seeking a margin of safety. This analysis is purely observational and should not be construed as financial advice or a recommendation to buy or sell Wanbury shares.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Wanbury Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of WANBURY across key market metrics for learning purposes.
Positive Indicators
8 factors identified
Strong Return on Equity (76.52%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (36.68%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Attractive Valuation (P/E: 20.82 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (1197.12%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (24.46%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Excellent EPS Growth (27.81% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (30.94% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Strong Cash Generation (₹29.50 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Risk Factors
5 factors identified
Elevated Debt Levels (D/E: 3.02)
Observation: High leverage increases financial risk and interest burden.
Analysis: High debt-to-equity ratios require monitoring of debt servicing capability.
Weak Interest Coverage (2.14x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Limited Institutional Interest (FII+DII: 0.80%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
High Share Pledging Risk (71.73%)
Observation: Significant promoter share pledging creates potential overhang.
Analysis: High pledging levels may create selling pressure during market downturns.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Wanbury Ltd Financial Statements
Comprehensive financial data for Wanbury Ltd including income statement, balance sheet and cash flow
About WANBURY (Wanbury Ltd)
Wanbury Ltd is a pharmaceutical company driven by innovation and a commitment to improving healthcare outcomes across the globe. The company formulates, develops, manufactures, and... markets a diverse portfolio of pharmaceutical products including formulations and active pharmaceutical ingredients (APIs). Wanbury addresses a range of therapeutic areas, providing solutions for common and complex health challenges. With a dedication to quality and patient well-being, the company strives to deliver effective and accessible medicines that enhance the lives of people worldwide. Wanbury's integrated approach encompasses research and development, manufacturing excellence, and strategic partnerships, all of which contribute to its sustained growth and success in the competitive pharmaceutical landscape. Wanbury's formulation offerings cover a wide range of medical needs, from managing common ailments to addressing more specialized conditions. Its anti-infective range battles bacterial and viral infections, while its pain and analgesics provide relief for various types of discomfort. Wanbury's product lineup also includes formulations for respiratory conditions, gastroenterological disorders, gynecological health, rheumatological issues, and central nervous system disorders. The company understands the importance of overall health and well-being, and it also provides a comprehensive range of vitamins, minerals, and nutritional supplements. By addressing diverse therapeutic needs, Wanbury plays a vital role in promoting health and improving the quality of life for patients across different demographics. Wanbury's API division plays a crucial role in the pharmaceutical supply chain, providing essential ingredients for a variety of medications. The company manufactures APIs for antidiabetics, helping to manage blood sugar levels in diabetic patients. It also produces APIs for antihistamines, offering relief from allergy symptoms, and for antitussives, which alleviate coughs. Wanbury's API portfolio extends to analgesics, antidepressants, and anti-inflammatory medicines, supporting the production of drugs that address pain, mood disorders, and inflammation. Through its commitment to quality and reliability, Wanbury contributes to the availability of effective and affordable medications, empowering healthcare professionals and patients alike.
Company Details
Key Leadership
Corporate Events
WANBURY Share Price: Frequently Asked Questions
What is the current share price of Wanbury Ltd (WANBURY)?
As of 30 Mar 2026, 12:04 pm IST, Wanbury Ltd share price is ₹221.95. The WANBURY stock has a market capitalisation of ₹895.00 (Cr) on NSE/BSE.
Is WANBURY share price Overvalued or Undervalued?
WANBURY share price is currently trading at a P/E ratio of 20.82x, compared to the industry average of 31.77x. Based on this relative valuation, the Wanbury Ltd stock appears to be Undervalued against its sector peers.
What is the 52-week high and low of WANBURY share price?
The 52-week high of WANBURY share price is ₹329.70 and the 52-week low is ₹161.50. These values are updated daily from NSE/BSE price data.
What factors affect the Wanbury Ltd share price?
Key factors influencing WANBURY share price include quarterly earnings growth (Sales Growth: 24.46%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Wanbury Ltd a good stock for long-term investment?
Wanbury Ltd shows a 5-year Profit Growth of 30.94% and an ROE of 76.52%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 3.02 before investing in WANBURY shares.
How does Wanbury Ltd compare with its industry peers?
Wanbury Ltd competes with major peers in the Pharmaceuticals. Investors should compare WANBURY share price P/E of 20.82x and ROE of 76.52% against the industry averages to determine competitive standing.
What is the P/E ratio of WANBURY and what does it mean?
WANBURY share price has a P/E ratio of 20.82x compared to the industry average of 31.77x. Investors pay ₹21 for every ₹1 of annual earnings.
How is WANBURY performing according to Bull Run's analysis?
WANBURY has a Bull Run fundamental score of 37.6/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does WANBURY belong to?
WANBURY operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Wanbury Ltd share price.
What is Return on Equity (ROE) and why is it important for WANBURY?
WANBURY has an ROE of 76.52%, which indicates excellent management efficiency. ROE measures how efficiently Wanbury Ltd generates profits from shareholders capital.
How is WANBURY debt-to-equity ratio and what does it indicate?
WANBURY has a debt-to-equity ratio of 3.02, which indicates high leverage that increases financial risk.
What is WANBURY dividend yield and is it a good dividend stock?
WANBURY offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Wanbury Ltd shares.
How has WANBURY share price grown over the past 5 years?
WANBURY has achieved 5-year growth rates of: Sales Growth 10.29%, Profit Growth 30.94%, and EPS Growth 27.81%.
What is the promoter holding in WANBURY and why does it matter?
Promoters hold 39.63% of WANBURY shares, with 71.73% pledged. High promoter holding often indicates strong management confidence in Wanbury Ltd.
What is WANBURY market capitalisation category?
WANBURY has a market capitalisation of ₹895 crores, placing it in the Small-cap category.
How volatile is WANBURY stock?
WANBURY has a beta of N/A. A beta > 1 suggests the Wanbury Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is WANBURY operating profit margin trend?
WANBURY has a 5-year average Operating Profit Margin (OPM) of 9.18%, indicating the company's operational efficiency.
How is WANBURY quarterly performance?
Recent quarterly performance shows Wanbury Ltd YoY Sales Growth of 24.46% and YoY Profit Growth of 1197.12%.
What is the institutional holding pattern in WANBURY?
WANBURY has FII holding of 0.80% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the Wanbury Ltd stock.